CorMedix Inc. Strengthens Its Market Presence
CorMedix Inc., an innovative biopharmaceutical company, is thrilled to announce an important development that enhances its position in the market. The company has finalized a new commercial supply contract with a major mid-sized dialysis operator. This agreement will facilitate the broader distribution of DefenCath (taurolidine and heparin) to dialysis clinics throughout the nation, aiming to improve access for adults experiencing kidney failure who are undergoing hemodialysis via a central venous catheter.
Improving Patient Care with DefenCath
This contract marks a significant advancement in the delivery of DefenCath, a crucial product created to address catheter-related bloodstream infections (CRBSI) for patients who need chronic hemodialysis. Thanks to this new partnership, over 250 outpatient dialysis centers across the United States will soon have DefenCath available for those who need it most. Shipments are anticipated to commence at the start of the fourth quarter, ensuring this life-saving product reaches patients promptly.
Recent Product Approvals and Market Availability
CorMedix Inc. has made impressive progress since securing NDA approval for DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs. After receiving FDA approval, the product became available in inpatient settings and is now being introduced into outpatient facilities. Reimbursement from the Center for Medicare & Medicaid Services (CMS) for outpatient treatment is also set to enhance accessibility and distribution.
Statements from Leadership
Joseph Todisco, the CEO of CorMedix, shares his enthusiasm regarding this development. He notes, "We've made significant strides in recent months in operationalizing existing customers while signing new agreements with top-tier dialysis providers across the U.S. I'm excited about the upward trend we're noticing for product utilization among early adopters, and I’m hopeful about the potential that these new relationships will unleash." This showcases the company’s dedication to growth and improving patient outcomes.
Important Safety Information
While DefenCath plays a vital role in patient health, understanding the associated safety parameters is crucial. The drug is specifically approved to reduce the incidence of catheter-related infections for adults undergoing chronic hemodialysis. However, it is contraindicated for patients with a known heparin-induced thrombocytopenia (HIT) and for those who are allergic to its components.
Using DefenCath
The administration of DefenCath should always be supervised by healthcare professionals to minimize any potential risks. If any adverse effects arise, it is advisable to stop the treatment and adopt appropriate supportive measures. Patients or caregivers who notice any safety concerns should reach out to CorMedix directly or report the issue to the FDA.
More About CorMedix
CorMedix Inc. continues to be committed to advancing therapeutic solutions for the prevention and treatment of complex conditions. The company’s key product, DefenCath, reflects its dedication to innovation and improving treatment practices for kidney failure patients. CorMedix not only aims to strengthen its existing product offerings but also seeks to investigate additional applications of DefenCath for various patient populations.
Frequently Asked Questions
What is CorMedix Inc. known for?
CorMedix Inc. is a biopharmaceutical company dedicated to developing therapeutic products for life-threatening conditions, with a focus on the product DefenCath.
What is DefenCath used for?
DefenCath is intended to decrease the incidence of catheter-related bloodstream infections in patients who are undergoing chronic hemodialysis.
When will the new supply of DefenCath begin?
Shipments of DefenCath under the new commercial agreement are expected to kick off at the beginning of the fourth quarter.
Where will DefenCath be available?
DefenCath will be accessible at more than 250 outpatient dialysis clinics across the United States as part of the new supply agreement.
How can safety concerns regarding DefenCath be reported?
Safety concerns or suspected adverse reactions can be reported to CorMedix at 1-888-424-6345 or to the FDA at 1-800-FDA-1088.
